Metastatic Colorectal Cancer clinical trials in California

Exercise program to prevent colorectal cancer after prostate radiation

This study tests whether an exercise program can help prevent colorectal cancer in men who have had pelvic radiation for prostate cancer. It involves using an iPhone app to track activity and attending exercise sessions.

Testing azirkitug for lung, head/neck, and other solid cancers

This Phase 1 study tests how a new medicine (azirkitug) behaves in the body and how safe it is, given by IV infusion alone or with other cancer drugs. It may help people with several advanced solid tumor cancers, especially after standard treatments have stopped working.

RAS inhibitors with ivonescimab for solid tumors

This trial tests new drugs called RAS(ON) inhibitors combined with ivonescimab for people with solid tumors that have a RAS mutation. It aims to see if this combination can shrink tumors or slow their growth.

Study of MCLA-158 for advanced solid tumors

This trial tests a new experimental drug called MCLA-158 (petosemtamab) for people with advanced solid tumors, especially head and neck cancer or colorectal cancer, that have not responded to standard treatments. The study aims to see if this drug can shrink tumors or slow their growth.

ALE.P03 for advanced CLDN1-positive solid tumors

This trial tests a new drug, ALE.P03, for people with advanced or metastatic solid tumors that have a certain protein (CLDN1). The drug is given alone (monotherapy) to see if it can shrink tumors or slow their growth.

Testing DISP-10 for Advanced Gastrointestinal Cancers

This early-stage trial tests a new experimental therapy called DISP-10 in patients with advanced cancers of the stomach, esophagus, or colon that have spread. The goal is to see if this treatment can help shrink tumors and how safe it is.

Study of VS-7375 for KRAS G12D solid tumors

This trial tests a new oral drug called VS-7375 for people with advanced solid tumors that have a specific KRAS G12D mutation. The goal is to see if it can shrink tumors or slow their growth.

Testing a new drug for cancers with KRAS G12D mutation

This trial tests a new pill (LY3962673) for people whose cancer has a specific DNA change called KRAS G12D. The drug aims to block the faulty protein that helps the cancer grow, and the study will look at safety and whether the tumor shrinks.

T cell activator STAR0602 for advanced solid tumors

This study tests an experimental drug called STAR0602 that aims to boost your immune system's T cells to fight advanced solid tumors. It's for patients whose cancer has not responded to standard treatments or for whom such treatments are not suitable.

Testing a targeted pill for hard-to-treat solid tumors

This trial tests a new medicine (Q901) that targets a specific cell-control pathway to treat advanced cancers that have stopped responding to standard care. It’s mainly for people with certain solid tumor cancers, aiming to see whether the drug can shrink tumors or control disease.

A study of MK-2870 for several gastrointestinal cancers

This trial is testing a new drug called MK-2870, alone or with other treatments, for people with advanced colorectal, pancreatic, or bile duct cancer. It aims to see if the drug can help shrink or control the cancer.

First drug test for metastatic uveal melanoma with specific gene changes

This Phase 1/2 trial studies IDE196 in adults with metastatic uveal melanoma that has certain gene mutations or fusions. It’s mainly testing safety and correct dosing, and may help shrink tumors in patients matched to the tumor’s genetic changes.

KO-2806 for advanced solid tumors

This trial tests a new drug called KO-2806, alone or with other treatments, for people with advanced solid tumors that have specific gene changes (like HRAS or KRAS mutations). It may help if standard treatments have stopped working.

Study of spevatamig for advanced gastrointestinal cancers

This trial tests a new drug called spevatamig (PT886) alone or with other treatments for advanced stomach, gastric, pancreatic, bile duct, or colorectal cancers. The goal is to see if it helps slow or stop cancer growth.

Testing two targeted drugs for KRAS G12C advanced cancer

This study tests two oral medicines (elironrasib and daraxonrasib) given alone or together to see if they can shrink tumors or slow down cancer growth in people with advanced solid tumors that have a KRAS G12C mutation. It is for people who have already tried other treatments.

Study of RMC-9805 for KRAS G12D solid tumors

This trial tests an experimental pill (RMC-9805) for people with solid tumors that have a specific KRAS G12D mutation. It's for those who have already tried other treatments and need new options.

Study of a new treatment for KRAS G12D cancers

This trial tests a new type of cell therapy (called TCR-T) that targets a specific genetic change (KRAS G12D) in advanced solid tumors that have stopped responding to standard treatments. It may be an option if your cancer has this mutation and you have a specific tissue type (HLA).

Pembrolizumab for advanced colorectal or lung cancer

This study tests pembrolizumab (an immune system medicine) with another treatment (TATE) in people with advanced colorectal or lung cancer that is not driven by certain gene changes. It may help shrink tumors after standard chemotherapy has stopped working.

Study of EIK1005 for advanced solid tumors

This study tests an experimental drug called EIK1005, either alone or combined with another drug (pembrolizumab), for people with advanced solid tumors, especially those with MSI-H or dMMR cancers (tumors that have trouble repairing their DNA). The goal is to see if it can shrink tumors or slow cancer growth.

Testing a new cancer drug for advanced solid tumors

This early-phase trial tests how well a new drug (BMS-986340) works alone and combined with other treatments in people with advanced solid tumors that have progressed despite standard care. It also studies tumor samples to look for biomarkers that may predict who benefits.

Test apheresis for CAR T manufacturing in HLA-A2 solid tumors

This trial studies how a process called apheresis is used to make CAR T cells for people with certain solid tumors. It is designed for tumors that have lost a specific immune marker (HLA-A*02), which may affect how well CAR T therapies work.

New Immunotherapy Drugs Before Surgery for Advanced Colorectal Cancer

This trial tests two immunotherapy drugs (botensilimab and balstilimab) given before surgery to treat advanced colorectal cancer that can be removed. The goal is to help the immune system fight cancer cells and improve outcomes after surgery.

A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors

Early trial drug for advanced solid tumors

This Phase 1 study tests CPO301 in adults with advanced or metastatic solid tumors that have worsened or cannot be treated with standard options. It aims to find the safest dose and understand how the treatment affects tumors, especially in certain lung cancer groups.